The Chicago Entrepreneur

Pfizer RSV vaccine for infants has ‘generally favorable’ safety data, FDA staff say

The FDA is slated to make a decision on whether to approve Pfizer’s shot in August before respiratory syncytial virus season in the fall. 

Previous post CNN’s CEO stands by Trump town hall but acknowledges production weaknesses, sources say
Next post : Fed funds futures traders boost odds of June Fed rate hike after April’s retail-sales data